Clinical trial · Interventional
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial
NCT03151057CI-TRIAL-00074914terminatedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Safety endpointreached
Summary
Brief summary (as posted)
This is a study to evaluate the safety of idelalisib as post-transplantation maintenance in patients with B cell hematologic malignancies undergoing a allogeneic hematopoietic stem cell transplant (HSCT). Safety will be evaluated through the assessment of cytopenias, effect on donor chimerism, effect on the incidence and severity of acute graft versus host disease, and gastro-intestinal tolerance.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B Cell Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| B Cells-Tumors | — | UNRESOLVED | — |
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) | — | UNRESOLVED | — |
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Idelalisib 100 MG | Drug | Idelalisib | ALIAS |
| Placebo Oral Tablet | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Idelalisib 100mg
- description
- Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies. intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
- interventionNames
- Drug: Idelalisib 100 MG
- type
- PLACEBO_COMPARATOR
- label
- Placebo oral tablet
- description
- Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
- interventionNames
- Drug: Placebo Oral Tablet
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
INCLUSION CRITERIA 1. \>18 years of age 2. Has undergone allo HSCT to treat a B-cell derived hematologic malignancy: accepted alloHSCT regimens include: myeloablative or reduced intensity conditioning from any donor (matched, partially mismatched or cord) and any source (peripheral blood, bone marrow, or cord). 3. T bili ≤ 1.5 mg/dL except for patients with Gilbert's syndrome or hemolysis 4. AST, ALT and alk phos all \< 2.5X ULN 5. Karnofsky performance score ≥ 40 6. ECOG ≤3 7. For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication. 8. Use of two forms of contraception with less than a 5% failure rate or abstinence by all transplanted patients for a minimum of 1 month after the last dose of Idelalisib. For the first 60 days post-transplant, transplant recipients should be encouraged to use non-hormonal contraceptives due to the potential adverse effect of hormones on bone marrow engraftment. 9. Ability to receive oral medication. 10. Ability to understand and provide informed consent. EXCLUSION CRITERIA 1. ECOG \>3 (Karnofsky \<40%) 2. ALT, AST \>2.5 ULN or total bilirubin \>1.5 ULN (not attributable to Gilbert's) 3. Women who are pregnant or breastfeeding. 4. Exclude if patient has cirrhosis or is currently being actively treated for hepatitis C. 5. History of positive HIV-1 or HIV-2 serologies or nucleic acid test. 6. Active hepatitis B infection as documented by positive Hepatitis B PCR assay 7. Use of investigational drug, other than the study medications specified by the protocol, within 30 days of transplantation. 8. Receipt of a live vaccine within 30 days of receipt of study therapy. 9. ≥ Grade II aGVHD 10. The presence of any medical condition that the Investigator deems incompatible with participation in the trial 11. Subjects who are required to use a medication classified as a strong CYP3A inducer of inhibitor.
References
Publications (0)
Data not yet available
No reference posted for this study.